Shots:

• The two P-III study involves assessing of Dupixent + SOC vs PBO (nasal spray alone) in adults with CRSwNP & Dupixent + mometasone furoate nasal spray (MFNS) vs MFNS in patients with bilateral nasal polyps
• Two P-III (SINUS-24 & SINUS-52) study results: improvement in nasal congestion/obstruction (-1.25 &-1.34 vs -0.38 and -0.45); reduction in their nasal polyps (-1.71 & -1.89 vs 0.10 & 0.17); improved lung function and asthma control
• Dupixent is a mAb- indicated for uncontrolled moderate-to-severe atopic dermatitis and globally jointly developed by Regeneron and Sanofi

Ref: Regeneron | Image: MultiVu